Visit to Klang manufacturing facility held in conjunction with 14th SMIIC Technical Committee Week 2025 in Kuala Lumpur -- ...
Zenas Biopharma’s lead autoimmune drug has been tied to a 95% reduction in a type of brain lesions over 12 weeks in a phase 2 multiple sclerosis (MS) study. | Zenas Biopharma’s lead autoimmune drug ...
Metis' MTS-004 was safe and eased symptoms of pseudobulbar affect in people with MS and other neurological disorders, trial data show.
Sheila Gujrathi, former CEO of Gossamer Bio, has written a new book that aims to offer the type of leadership manual she ...
VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug ...
The 2025 Prix Galien Africa has honoured Côte d’Ivoire’s La Ruche Health, led by Mr. Rory Assandey, for its groundbreaking ...
News-Medical.Net on MSN
First multiple sclerosis patient in the UK receives CAR T cell therapy in groundbreaking trial
A multiple sclerosis (MS) patient in the UK was the first to receive CAR T cell therapy, invented by UCL researchers, in a ...
Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback